Dr. Reddy’s API plant in Hyderabad gets VAI classification from U.S. FDA 


Photo: Special Arrangement

Photo: Special Arrangement

An active pharmaceutical ingredients (API) manufacturing facility of Dr. Reddy’s Laboratories in Hyderabad inspected last year by the United States Food and Drug Administration (U.S. FDA) has since been classified as Voluntary Action Indicated (VAI) by the agency.

“The U.S. FDA has classified the inspection as VAI and concluded that the inspection is closed…,” the generic drugmaker on Tuesday (February 25, 2025) said in an update to the stock exchanges on the inspection of the API manufacturing facility (CTO-2) in Bollaram, Hyderabad.

The U.S. FDA had conducted the GMP inspection from November 13-19 and issued a Form 483 with seven observations to the facility.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *